Features
OCTA Findings in Pediatric Patients With X-Linked Retinoschisis
Imaging reveals hyporeflective cysts and loss in the foveal avascular zone.
By Nimesh A. Patel, MD, Camila V. Ventura, MD, PhD, Linda A. Cernichiaro-Espinosa, MD, et al.
Management of Ocular Trauma
Preventive measures and expedited treatment are critical.
By Neelakshi Bhagat, MD, Tony Chen, MD, Marco A. Zarbin, MD, PhD
Vitrectomy in Nontractional Macular Edema
Is there a rationale?
By Stefano Ranno, MD, Edoardo Ruggiero
Remote Retinal Monitoring in the Time of COVID-19
Decreasing clinic visits keeps patients safer and streamlines care.
By Anat Loewenstein, MD, MHA
Tips and Tricks for Scleral Buckles in the 21st Century
Nuanced techniques for an essential skill.
By Stefano Ranno, MD, Edoardo Ruggiero, Kyle Kovacs, MD, et al.
A Review of Photic Retinopathy
The dangers of light.
By Hong-Uyen Hua, MD, Jason Fan, MD, PhD, Nika Bagheri, MD
Working With Imaging Centers for Clinical Research
Tips for investigators from the experts.
By Jennifer Tourtellot, CRA, OCT-C, Margaret Graham, Cindy Novalis
Web Exclusives
The Capabilities of Navigation in Microsecond Pulsing Laser Therapy
Preplanning and documentation may facilitate more predictable treatment.
By Pradeep S. Prasad, MD, and
Departments
CLINICAL TRIAL DOWNLOAD: Data on QR-421a for Inherited Retinal Disease
ProQR reported positive results for its antisense oligonucleotide.
By Yasha Modi, MD
CODING Q&A: Coding for Diagnostic Tests Whose Results Are Normal
Who pays for normal tests?
By Suzanne L. Corcoran, COE
NEW PRODUCT APPLICATIONS: TissueBlue Is a Game Changer for Staining the ILM
Brilliant blue G has been clinically proven to be reliable, predictable, and safe.
By Karen Appold, contributing writer
News
Beovu Gets FDA Label Update With Warnings
By Jerry Helzner, contributing editor
DARPin Fails to Get Approval Due to Inflammation Issue
Wet AMD therapy had advantage of durability.
By Jerry Helzner, contributing editor
Editorial Calls for Halting Use of Beovu
Novartis disagrees, calls drug important treatment option.
By Jerry Helzner, contributing editor
SUBSPECIALTY NEWS: Gene therapy, new treatments, and coronavirus impact on retina practice.
By Jerry Helzner, contributing editor